Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer

Daryush Purrahman; Mohammad-Reza Mahmoudian-Sani; Najmaldin Saki; Piotr Wojdasiewicz; Iwona Kurkowska-Jastrzębska; Łukasz A Poniatowski

doi:10.1016/j.cyto.2022.155803

Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer

Cytokine. 2022 Mar:151:155803. doi: 10.1016/j.cyto.2022.155803. Epub 2022 Jan 20.

Authors

Daryush Purrahman¹, Mohammad-Reza Mahmoudian-Sani², Najmaldin Saki³, Piotr Wojdasiewicz⁴, Iwona Kurkowska-Jastrzębska⁵, Łukasz A Poniatowski⁶

Affiliations

¹ Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Electronic address: daryushpurrahman@gmail.com.
² Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Clinical Research Development Unit, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Electronic address: mohamadsani495@gmail.com.
³ Thalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Electronic address: najmaldinsaki@gmail.com.
⁴ Department of Biophysics, Physiology and Pathophysiology, Faculty of Health Sciences, Medical University of Warsaw, Chałubińskiego 5, 02-004 Warsaw, Poland. Electronic address: pwojdasiewicz@gmail.com.
⁵ 2nd Department of Neurology, Institute of Psychiatry and Neurology, Sobieskiego 9, 02-957 Warsaw, Poland. Electronic address: ikurkowska@ipin.edu.pl.
⁶ Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Banacha 1B, 02-097 Warsaw, Poland; Department of Neurosurgery, Maria Skłodowska-Curie National Research Institute of Oncology, W. K. Roentgena 5, 02-781 Warsaw, Poland. Electronic address: lukasz.poniatowski@gmail.com.

PMID: 35066450
DOI: 10.1016/j.cyto.2022.155803

Abstract

Breast cancer constitute a common type of oncological disease with a highlighted mortality rate. In recent years, researchers have introduced progranulin (PGRN) as an novel potential biomarker and associated its function with higher risk factor for development of breast cancer. The present review article collects evidence on the association of PGRN with clinicopathological features and drug resistance in the patients with breast cancer. The results of this study suggested the use of routine determination of PGRN in the clinic as a reliable biomarker for screening people at high risk or as early indication of breast cancer. Targeting PGRN and its associated signaling pathways and receptors, such as sortilin (SORT1), could also cover a novel therapeutic strategy in the breast cancer.

Keywords: Biomarker; Breast cancer; Cancer drug resistance; Metastasis; Progranulin.

Publication types

Review

MeSH terms

Breast Neoplasms* / pathology
Female
Humans
Prognosis
Progranulins / metabolism

Substances

Progranulins